FRANKLIN LAKES, N.J. and
AUSTIN, Texas, Feb. 12, 2020 /PRNewswire/ -- BD (Becton,
Dickinson and Company) (NYSE:
BDX), a leading global medical technology company and Babson
Diagnostics, a transformative diagnostic blood testing company,
today announced a long-term strategic partnership agreement to
bring laboratory-quality, small-volume blood collection to retail
pharmacies.
The partnership reflects emerging health care trends toward
faster, less expensive laboratory testing in customer-friendly
health care settings with more convenient hours and locations, as
well as rapid growth in the diagnostic testing market. The
partnership builds on a collaboration between the two companies
dating back to 2017. Its goal is to enable retail pharmacies to
offer laboratory-quality diagnostic testing through Babson
Diagnostics' service by combining BD's innovative capillary blood
collection device in development with Babson Diagnostics'
proprietary automated sample handling and analytical technologies,
which are also in development.
BD's new capillary specimen collection device in development is
designed to enable the collection of laboratory-quality specimens
without the need to access a vein. Drawing from more than 70 years
of specimen management success with BD Vacutainer® devices, the
small-volume blood collection devices being developed by BD will be
designed for health care settings without a trained phlebotomist,
such as retail pharmacies, physician offices, urgent care centers
and skilled nursing facilities.
"BD has been a leader in blood collection technology with a long
history of global innovation," said Eric
Olson, chief executive officer of Babson Diagnostics. "The
technology they are developing is critical to Babson's mission of
making diagnostic blood testing more convenient and accessible
without sacrificing accuracy or cost. Combining this technology
with our own will allow us to bring diagnostic blood testing to
retail pharmacies, making it easier for people to gain control over
and improve their health."
Babson Diagnostics' diagnostic blood testing model is designed
to allow customers to get physician-ordered or self-ordered
diagnostic blood tests at convenient retail pharmacies. In such a
setting, customers can avoid long wait times and may benefit from
longer hours of operation, low out-of-pocket costs, and a more
pleasant blood collection experience.
"Patient expectations for health care are evolving, and patients
are demanding care in more convenient settings. With our specimen
management innovations, we hope to revolutionize diagnostic testing
to meet patient expectations with laboratory-quality tests that can
be performed with small blood samples that do not require
venipuncture," said Patrick
Kaltenbach, executive vice president and president, life
sciences at BD. "Babson Diagnostics will help bring BD's
advanced capillary blood collection products to emerging health
care settings, making laboratory-quality diagnostics more
accessible to patients in the U.S. and around the world."
Babson Diagnostics and BD are undertaking clinical studies on
these devices in retail pharmacy settings. BD plans to prepare
regulatory submissions to the U.S. Food and Drug Administration and
other global regulatory bodies upon completion of these clinical
studies.
About BD
BD is one of the largest global medical technology companies in
the world and is advancing the world of health by improving medical
discovery, diagnostics and the delivery of care. The company
supports the heroes on the frontlines of healthcare by developing
innovative technology, services and solutions that help advance
both clinical therapy for patients and clinical process for
healthcare providers. BD and its 65,000 employees have a passion
and commitment to help enhance the safety and efficiency of
clinicians' care delivery process, enable laboratory scientists to
accurately detect disease and advance researchers' capabilities to
develop the next generation of diagnostics and therapeutics. BD has
a presence in virtually every country and partners with
organizations around the world to address some of the most
challenging global health issues. By working in close collaboration
with customers, BD can help enhance outcomes, lower costs, increase
efficiencies, improve safety and expand access to healthcare.
For more information on BD, please visit bd.com.
About Babson Diagnostics
Babson Diagnostics aims to bring diagnostic blood testing to the
retail pharmacy counter, making it easier, faster, and more
pleasant for customers to routinely monitor and improve their
health. Babson's proprietary technological ecosystem is designed to
deliver accurate diagnostic results with a more human experience.
Based in Austin, Texas, its vision
for diagnostic blood testing—built on accuracy, convenience, and
accessibility—combines transformative diagnostic technology with a
customer-first, retail-centric business model that aims to improve
customer health and experience. Prior to commercialization, Babson
Diagnostics is working with local and national retail pharmacies to
validate its technology by conducting clinical studies intended for
peer-reviewed publication. For more information on Babson
Diagnostics, please visit www.babsondx.com.
Contacts:
|
|
|
Gwen
Gordon
|
Monique N.
Dolecki
|
|
BD Public
Relations
|
BD Investor
Relations
|
|
858.617.2897
|
201.847.5378
|
|
gwen.gordon@bd.com
|
monique_dolecki@bd.com
|
|
|
|
|
Emma Chase
|
|
|
Babson
Diagnostics
|
|
|
512.917.4319
|
|
|
pr@babsondx.com
|
|
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bd-babson-diagnostics-announce-strategic-partnership-agreement-to-enable-small-volume-blood-collection-for-diagnostic-testing-in-retail-settings-301003377.html
SOURCE BD (Becton, Dickinson
and Company)